No Clinical Benefit of Empirical Antimicrobial Therapy for Pediatric Diarrhea in a High-Usage, High-Resistance Setting
Open Access
- 26 September 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 66 (4), 504-511
- https://doi.org/10.1093/cid/cix844
Abstract
Pediatric diarrheal disease presents a major public health burden in low- to middle-income countries. The clinical benefits of empirical antimicrobial treatment for diarrhea are unclear in settings that lack reliable diagnostics and have high antimicrobial resistance (AMR). We conducted a prospective multicenter cross-sectional study of pediatric patients hospitalized with diarrhea containing blood and/or mucus in Ho Chi Minh City, Vietnam. Clinical parameters, including disease outcome and treatment, were measured. Shigella, nontyphoidal Salmonella (NTS), and Campylobacter were isolated from fecal samples, and their antimicrobial susceptibility profiles were determined. Statistical analyses, comprising log-rank tests and accelerated failure time models, were performed to assess the effect of antimicrobials on disease outcome. Among 3166 recruited participants (median age 10 months; interquartile range, 6.5–16.7 months), one-third (1096 of 3166) had bloody diarrhea, and 25% (793 of 3166) were culture positive for Shigella, NTS, or Campylobacter. More than 85% of patients (2697 of 3166) were treated with antimicrobials; fluoroquinolones were the most commonly administered antimicrobials. AMR was highly prevalent among the isolated bacteria, including resistance against fluoroquinolones and third-generation cephalosporins. Antimicrobial treatment and multidrug resistance status of the infecting pathogens were found to have no significant effect on outcome. Antimicrobial treatment was significantly associated with an increase in the duration of hospitalization with particular groups of diarrheal diseases. In a setting with high antimicrobial usage and high AMR, our results imply a lack of clinical benefit for treating diarrhea with antimicrobials; adequately powered randomized controlled trials are required to assess the role of antimicrobials for diarrhea.Funding Information
- Wellcome Trust (100087/Z/12/Z)
This publication has 31 references indexed in Scilit:
- Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010The Lancet, 2013
- Increasing Antimicrobial Resistance of Campylobacter Jejuni Isolated from Paediatric Diarrhea Cases in A Tertiary Care Hospital of New Delhi, IndiaJournal of Clinical and Diagnostic Research, 2013
- Epidemiological features and risk factors ofSalmonellagastroenteritis in children resident in Ho Chi Minh City, VietnamEpidemiology and Infection, 2012
- Campylobacterantimicrobial resistance in Peru: a ten-year observational studyBMC Infectious Diseases, 2012
- High content live cell imaging for the discovery of new antimalarial marine natural productsBMC Infectious Diseases, 2012
- High burden of antimicrobial resistance in AsiaInternational Journal of Antimicrobial Agents, 2011
- Antibiotics for the treatment of dysentery in childrenInternational Journal of Epidemiology, 2010
- A changing picture of shigellosis in southern Vietnam: shifting species dominance, antimicrobial susceptibility and clinical presentationBMC Infectious Diseases, 2009
- A Meta-Analysis on the Effects of Antibiotic Treatment on Duration of Symptoms Caused by Infection with Campylobacter SpeciesClinical Infectious Diseases, 2007
- A Multicentre Study of Shigella Diarrhoea in Six Asian Countries: Disease Burden, Clinical Manifestations, and MicrobiologyPLoS Medicine, 2006